1-chloro-2-(4-nitrobenzyl)benzene | 96749-76-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-chloro-2-(4-nitrobenzyl)benzene
• 英文别名: 2-Chlor-4'-nitro-diphenylmethan；(2-chloro-phenyl)-(4-nitro-phenyl)-methane；(2-Chlor-phenyl)-(4-nitro-phenyl)-methan；1-Chloro-2-[(4-nitrophenyl)methyl]benzene
• CAS: 96749-76-7
• 化学式: C₁₃H₁₀ClNO₂
• 分子量: 247.681
• InChiKey: YDTOFCDPVTYXAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-chloro-2-(4-nitrobenzyl)benzene 在 溶剂黄146 、 锌 作用下， 反应 0.5h， 生成 4-(2-chlorobenzyl)aniline
  参考文献：
  名称：

  Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors

  摘要：

  Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto-enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited marked antiretroviral activity. Here, we show the synthesis and the detailed structure-activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)- 1-((2,S)-1-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-4-oxo- 1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nM in the strand transfer assay and an ED50 of 0.6 nM in the antiviral assay, and 6-(3-chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-4-dihydroquinoline-3-carboxylic acid 49, which had an IC50 of 7.2 nM and an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrase-catalyzed strand transfer processes than 3'-processing reactions, as is the case with the keto-enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.

  DOI：

  10.1021/jm900460z
• 作为产物：
  描述：

  4-硝基碘苯 、 邻氯氯苄 在 三甲基氯硅烷 、 1,2-二溴乙烷 、 锌 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三(2-呋喃基)膦 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以76%的产率得到1-chloro-2-(4-nitrobenzyl)benzene
  参考文献：
  名称：

  [EN] AGRICULTURAL CHEMICALS
  [FR] PRODUITS CHIMIQUES AGRICOLES

  摘要：

  本发明涉及烟酸衍生物，用于治疗植物的真菌性病害。

  公开号：

  WO2019141980A1

文献信息

• (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0371564A2

  公开（公告）日：1990-06-06

  Novel (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives of formula the pharmaceutical acceptable acid addition salts thereof and the stereochemically isomeric forms thereof, wherein -X1 =X2- is -CH = CH-, -CH = N-, or -N = CH-; R is hydrogen or C1-6alkyl; Y is hydrogen, C1-10alkyl, C3-7cycloalkyl, Arl, Ar2-C1-6alkyl, C2-6alkenyl or C2-6alkynyl; Z is a radical of formula which compounds are useful for treating disorders which are characterized by an excessive proliferation and/or abnormal differentiation of epithelial tissues: pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的新型(1H-唑-1-基甲基)取代的喹啉、喹唑啉或喹喔啉衍生物 其中 -X1 =X2- 是 -CH = CH-、-CH = N-或 -N = CH-；R 是氢或 C1-6 烷基；Y 是氢、C1-10 烷基、C3-7 环烷基、Arl、Ar2-C1-6 烷基、C2-6 烯基或 C2-6 烷炔基；Z 是式中的一个基团 这些化合物可用于治疗以上皮组织过度增殖和/或异常分化为特征的疾病：含有此类化合物作为活性成分的药物组合物，以及制备所述化合物和药物组合物的方法。
• Farnesyl transferase inhibiting 2-quinolone derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP1106610A1

  公开（公告）日：2001-06-13

  The present invention is concerned with compounds of formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1- 6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)-aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula -Alk1-C(=O)-R9, -Alk1-S(O)-R9 or -Alk1-S(O)2-R9; R2 and R3 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1- 6alkyloxy, C1-6alkyloxy-C1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1- 6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyl-oxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; or when on adjacent positions R2 and R3 taken together may form a bivalent radical; R4 and R5 each independently are hydrogen, Ar1, C1-6alkyl, C1-6alkyloxy-C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxy-carbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2-C1-6alkyl; R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy or Ar2oxy; R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkyl-carbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxy-carbonylC1-6alkyl, hydroxycarbonyl-C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, haloC1-6alkyl, C1-6alkyloxy-C1-6alkyl, aminocarbonylC1-6alkyl, Ar1, Ar2C1-6alkyl-oxyC1-6alkyl, C1-6alkylthioC1-6alkyl; R10 is hydrogen, C1-6alkyl or halo; R11 is hydrogen or C1-6alkyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及式（I）化合物、 其中虚线代表任选键；X 是氧或硫；R1是氢、C1-12烷基、Ar1、Ar2C1-6烷基、喹啉基C1-6烷基、吡啶基C1-6烷基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、单-或二(C1-6烷基)-氨基C1-6烷基、氨基C1-6烷基或式-Alk1-C(＝O)-R9、-Alk1-S(O)-R9或-Alk1-S(O)2-R9的基；R2和R3各自独立地为氢、羟基、卤代、氰基、C1-6烷基、C1-6烷氧基、羟基C1-6烷氧基、C1-6烷氧基-C1-6烷氧基、氨基C1-6烷氧基、一或二（C1-6烷基）氨基C1-6烷氧基、Ar1、Ar2C1-6烷基、Ar2氧基、Ar2C1-6烷氧基、羟基羰基、C1-6烷氧基羰基、三卤甲基、三卤甲氧基、C2-6烯基；或当 R2 和 R3 位于相邻位置时，可共同形成二价基；R4 和 R5 各自独立地为氢、Ar1、C1-6烷基、C1-6烷氧基-C1-6烷基、C1-6烷氧基、C1-6烷硫基、氨基、羟基羰基、C1-6烷氧基羰基、C1-6烷基S(O)C1-6烷基或 C1-6烷基S(O)2-C1-6烷基；R6 和 R7 各自独立地为氢、卤代、氰基、C1-6烷基、C1-6烷氧基或 Ar2oxy；R8 是氢、C1-6烷基、氰基、羟基羰基、C1-6烷氧基羰基、C1-6烷基-羰基-C1-6烷基、氰基 C1-6烷基、C1-6烷氧基-羰基-C1-6烷基、羟基羰基-C1-6烷基、羟基羰基-C1-6烷基、C1-6烷氧基-羰基-C1-6烷基或 Ar2oxy、羟基-C1-6烷基、氨基-C1-6烷基、单-或二(C1-6烷基)氨基-C1-6烷基、卤代-C1-6烷基、C1-6烷氧基-C1-6烷基、氨基羰基-C1-6烷基、Ar1、Ar2C1-6烷基-氧基-C1-6烷基、C1-6烷基硫代-C1-6烷基；R10为氢、C1-6烷基或卤代；R11为氢或C1-6烷基；具有法尼基转移酶抑制活性；它们的制备、含有它们的组合物以及它们作为药物的用途。
• Montagne, Chemische Berichte, 1916, vol. 49, p. 2274
  作者：Montagne

  DOI：——

  日期：——
• Boeseken, Recueil des Travaux Chimiques des Pays-Bas, 1904, vol. 23, p. 107
  作者：Boeseken

  DOI：——

  日期：——
• FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1019395B1

  公开（公告）日：2002-01-30